lobbying_activities: 2824625

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2824625	dd2d3682-a0e3-4555-867c-5a9633c77136	Q2	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	3457	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	2022	second_quarter	PHA	Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.	Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE		528641	0	0	2022-07-18T14:23:24-04:00